

Coegin Pharma Q2 - Broadening the portfolio

Redeye provides a research update following the Q2 report recently published by Coegin Pharma. While the report itself did not include any significant surprises, the main focus is on the newly acquired pigmentation peptide platform. As the company broadens its portfolio, we see increased potential in the stock. Accordingly, we revise our fair value range with a raised base case valuation of SEK10 (8.5).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Coegin Pharma Q2 - Broadening the portfolio](#)